Price
No data yet.
Social Signal Score
Revenue
$1.15MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Harry Simeonidis
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 59
- Beta
- 4.25
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -11.23
Financials
Revenue
$1.15MNet Income
$-3.91MEBITDA
$-3.92MFree Cash Flow
$-3.18MEPS (diluted)
$-1.34Shares Outstanding (diluted)
2.91M+84438.9%Operating Expenses
$4.46MCash & Debt
$3.99MReturn of Capital
$0.00Revenue by Segment (annual)
$578.6KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $4.22M | $-12.43M | $-8.44 |
| 2025 | $3.05M | $-10.57M | $-20.00 |
| 2024 | $3.11M | $-10.16M | $-63.80 |
| 2023 | $1.26M | $-10.63M | $-105.80 |
| 2022 | $0.00 | $-8.31M | $-113.30 |
| 2021 | $1.98M | $-7.04M | $-162.20 |
| 2020 | $188.7K | $-3.16M | $-89.20 |
| 2019 | $0.00 | $-7.34M | $-210.10 |
| 2018 | $0.00 | $-5.02M | $-146.00 |
| 2017 | $0.00 | $-340.0K | $-9.90 |
Valuation
INBShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
98-2.50%Social Signal Score
Mentions (6)
- Newsseekingalpha.com·11d ago·Neutral
Intelligent Bio Solutions Inc. (INBS) Discusses FDA 510(k) Submission and Progress of Intelligent Fingerprinting Drug Screening System Transcript Intelligent Bio Solutions Inc. (INBS) Discusses FDA 510(k) Submission and Progress of Intelligent Fingerprinting Drug Screening System Transcript
View source ↗ - Newsglobenewswire.com·26d ago·Negative
Intelligent Bio Solutions to Host Virtual Fireside Chat on September 24th at 4:30 p.m. ET Management to discuss FDA 510(k) submission, clinical data, and commercial progress outside the U.S. Management to discuss FDA 510(k) submission, clinical data, and commercial progress outside the U.S.
View source ↗ - Newsglobenewswire.com·27d ago·Negative
… Intelligent Fingerprinting Drug Screening System, Seeking U.S. Market Clearance NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the submission of its 510(k) premarket notification to the U.S. Food and Drug Administration (FDA), seeking regulatory clearance of its Intelligent Fingerprinting Drug Screening System (the “Sy…
View source ↗ - Newsglobenewswire.com·35d ago·Neutral
Intelligent Bio Solutions Achieves Above 98% Accuracy in Method Comparison Study, Supporting Planned 2026 FDA 510(k) Submission Multi-site clinical study delivers strong performance data for Intelligent Fingerprinting Drug Screening System Multi-site clinical study delivers strong performance data for Intelligent Fingerprinting Drug Screening System
View source ↗ - Newsglobenewswire.com·48d ago·Neutral
Intelligent Bio Solutions Reports Fiscal 2026 Full-Year Revenue Growth of 38% Year-over-Year, Driven by Reader Installed Base and High-Margin Cartridge Growth Reader installed base grew 22% year-over-year, driving a 35% increase in total consumable cartridges to over 100,000 units
View source ↗ - Newsbenzinga.com·49d ago·Neutral
Intelligent Bio Solutions Shares Surge Monday: What's Driving the Action? Shares of Intelligent Bio Solutions Inc. (NASDAQ:INBS) are surging Monday afternoon after the medical technology company announced a significant regulatory milestone for its rapid testing unit.
View source ↗
Earnings
Wed, Nov 11(in 5 weeks)
Consensus estimate $-1.31 per share
Typical surprise -133.3% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 19$-1.34 vs $-1.58beat
- Tue, May 12$-1.80 vs $1.40miss
- Thu, Feb 12$-2.82 vs $0.40miss
- Thu, Nov 13$-3.50 vs $-1.50miss
- Fri, Aug 15$-3.60 vs $-1.20miss
- Wed, May 14$-4.40 vs $-2.80miss
Estimates and results for INBS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by INBS officers and directors.
- Bought
- $67k
- Sold
- —
8 trades
0 trades
- Towers Christopherbought
- Towers Christopherbought
- Towers Christopherbought
- Sakiris Spiro Kevinbought
- Sakiris Spiro Kevinbought
- Sakiris Spiro Kevinbought
- Simeonidis Harrybought
- Simeonidis Harrybought
18 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in INBS.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.